Stephen Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on shared a post on X:
“Results from KROCUS study, The Lancet Oncology: first-line fulzerasib (KRAS G12C inhibitor) + cetuximab (anti-EGFR mAb) in KRAS G12C NSCLC (n=47). RR 69%, median treatment duration 10.1m, only 6% required discontinuation due to TRAE.
However, I have real concerns about omitting first-line immunotherapy in KRAS G12C NSCLC. A subset of patients will derive long-term (indefinite?) benefit from immunotherapy strategies.
I would not trade long-term survival for a regimen with a high response rate knowing that attrition at progression will prevent some patients from receiving later-line checkpoint inhibition. Since we are unable to identify who does or does not benefit, immunotherapy has to be the 1L standard in some form.”
Title: Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial
Authors: Vanesa Gregorc, Margarita Majem, Giuseppe Lo Russo, Michele Maio, Stephanie Salvagni, Vanesa Gutiérrez-Calderon, Maria Gonzalez-Cao, Sergio Sandiego Contreras, Anna Koumarianou, Alessandra Bearz, Reyes Bernabé-Caro, Santiago Viteri, Miguel Fernández de Sanmamed, Flora Zagouri, Teresa Morán Bueno, Chiara Lazzari, Sergio Martínez-Recio, Ana Giménez-Capitán, Yue Zhang, Yue Shan, Huaqiang Zhu, Congqiao Zhao, Haige Shen, Yu Wang, Rafael Rosell
Read the Full Article.
Other articles featuring Stephen Liu on OncoDaily.